ヘモグロビン異常症の世界市場規模および予測:タイプ別(アルファサラセミア、ベータサラセミア、鎌状赤血球症、Hb変異体疾患)、治療法別(輸血、鉄キレート療法、骨髄移植、ヒドロキシ尿素)、診断別(血液検査、遺伝子検査、出生前診断、着床前診断、ヘモグロビン電気泳動)、動向分析、2012-2022...市場調査レポートについてご紹介

【英文タイトル】Hemoglobinopathies Market Size & Forecast By Type (Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases), By Therapy (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Hydroxyurea), By Diagnosis (Blood Testing, Genetic Testing, Prenatal Genetic Testing, Pre-implantation Genetic Diagnosis, Hemoglobin Electrophoresis) And Trend Analysis From 2012 To 2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Content

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
1.4 Known, Unknown variables & target segment
Chapter 2 Executive Summary
Chapter 3 Hemoglobinopathies Industry Outlook
3.1 Market segmentation
3.2 Market size and growth prospects
3.3 Hemoglobinopathies : Market dynamics
3.3.1 Market Driver Analysis
3.3.1 Market Restraint Analysis
3.4 Key opportunity analysis, by type- 2014
3.5 Industry analysis Porter’s
3.6 Hemoglobinopathies : PESTEL Analysis
3.7 Hemoglobinopathies Market : Government Regulations
3.7.1 Sickle Cell Disease (SCD) drug development
3.7.2 Drug development for Thalassemia
3.8 Hemoglobinopathies Market: Need Gap Analysis
3.8.1 Prevalence
3.8.2 Treatment efficacy
3.8.3 Therapeutic gap
Chapter 4 Hemoglobinopathies Therapy Outlook
4.1 Hemoglobinopathies market share by therapy, 2014 & 2022
4.2 Thalassemia therapy
4.2.1 Thalassemia therapy market, 2012 – 2022 (USD Million)
4.2.2 Alpha thalassemia therapy
4.2.2.1 Alpha thalassemia therapy market, 2012 – 2022 (USD Million)
4.2.3 Beta thalassemia therapy
4.2.3.1 Beta thalassemia therapy market, 2012 – 2022 (USD Million)
4.3 Sickle Cell Disease (SCD) therapy
4.3.1 Sickle Cell Disease (SCD) therapy market, 2012 – 2022 (USD Million)
4.4 Other therapy
4.4.1 Other haemoglobin variants therapy market, 2012 – 2022 (USD Million)
Chapter 5 Hemoglobinopathies Diagnosis Outlook
5.1 Hemoglobinopathies market share by diagnosis, 2014 & 2022
5.2 Thalassemia diagnosis
5.2.1 Thalassemia diagnosis market, 2012 – 2022 (USD Million)
5.2.2 Alpha thalassemia diagnosis
5.2.2.1 Alpha thalassemia diagnosis market, 2012 – 2022 (USD Million)
5.2.3 Beta thalassemia diagnosis
5.2.3.1 Beta thalassemia diagnosis market, 2012 – 2022 (USD Million)
5.3 Sickle Cell Disease (SCD) diagnosis
5.3.1 Sickle Cell Disease (SCD) diagnosis market, 2012 – 2022 (USD Million)
5.4 Other hemoglobin variants
5.4.1 Other haemoglobin variants market, 2012 – 2022 (USD Million)
Chapter 6 Hemoglobinopathies Regional Outlook
6.1 Hemoglobinopathies market Share by Region, 2014 & 2022
6.2 North America
6.2.2 U.S.
6.2.4 Canada
6.3 Europe
6.3.1 Europe Hemoglobinopathies Market, 2012 – 2022 (USD Million)
6.3.2 UK
6.3.3 UK Hemoglobinopathies Market, 2012 – 2022 (USD Million)
6.3.4 Germany
6.3.5 Germany Hemoglobinopathies Market, 2012 – 2022 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Hemoglobinopathies Market, 2012 – 2022 (USD Million)
6.4.2 Japan
6.4.4 China
6.4.5 China Hemoglobinopathies Market, 2012 – 2022 (USD Million)
6.5 Latin America
6.5.1 Latin America Hemoglobinopathies Market, 2012 – 2022 (USD Million)
6.5.2 Brazil
6.5.3 Brazil Hemoglobinopathies Market, 2012 – 2022 (USD Million)
6.5.4 Mexico
6.5.5 Mexico Hemoglobinopathies Market, 2012 – 2022 (USD Million)
6.6 MEA
6.6.2 South Africa
6.6.3 South Africa Hemoglobinopathies Market, 2012 – 2022 (USD Million)
Chapter 7 Competitive Landscape
7.1 Gamida Cell
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Alnylam Pharmaceuticals
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Biogen Idec
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Sangamo BioSciences Inc.
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Genetix Pharmaceuticals/Bluebird Bio
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Global Blood Therapeutics Inc.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Pfizer Inc.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Mast Therapeutics
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
7.9 Emmaus Life Sciences, Inc.
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Product Benchmarking
7.9.4 Strategic Initiatives
7.10 Prolong Pharmaceuticals
7.10.1 Company Overview
7.10.2 Financial Performance
7.10.3 Product Benchmarking
7.10.4 Strategic Initiatives
7.11 Celgene Corporation
7.11.1 Company Overview
7.11.2 Financial Performance
7.11.3 Product Benchmarking
7.11.4 Strategic Initiatives
7.12 HemaQuest Pharmaceuticals
7.12.1 Company Overview
7.12.2 Financial Performance
7.12.3 Product Benchmarking
7.12.4 Strategic Initiatives


【レポート販売概要】

■ タイトル:ヘモグロビン異常症の世界市場規模および予測:タイプ別(アルファサラセミア、ベータサラセミア、鎌状赤血球症、Hb変異体疾患)、治療法別(輸血、鉄キレート療法、骨髄移植、ヒドロキシ尿素)、診断別(血液検査、遺伝子検査、出生前診断、着床前診断、ヘモグロビン電気泳動)、動向分析、2012-2022
■ 英文:Hemoglobinopathies Market Size & Forecast By Type (Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases), By Therapy (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Hydroxyurea), By Diagnosis (Blood Testing, Genetic Testing, Prenatal Genetic Testing, Pre-implantation Genetic Diagnosis, Hemoglobin Electrophoresis) And Trend Analysis From 2012 To 2022
■ 発行日:2016年2月22日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707392
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。